MXPA03010991A - Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. - Google Patents
Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.Info
- Publication number
- MXPA03010991A MXPA03010991A MXPA03010991A MXPA03010991A MXPA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A
- Authority
- MX
- Mexico
- Prior art keywords
- skin
- subject
- composition
- cox
- monohydric alcohol
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012088 reference solution Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica que se puede liberar dermicamente que comprende al menos, un farmaco o profarmaco del mismo, inhibidor de la ciclooxigenasa-2 (COX-2) selectivo, solubilizado en un portador farmaceuticamente aceptable que comprende un alcohol monohidrico de bajo peso molecular, y presenta una velocidad de permeacion en la piel del agente terapeutico al menos, igual a aquella presentada por una solucion de referencia del agente terapeutico en etanol acuoso al 70%. Un metodo para efectuar suministro objetivo de un farmaco inhibidor de COX-2 a un sitio de dolor y/o inflamacion en un sujeto, comprende administrar topicamente tal composicion a la piel del sujeto, preferiblemente en un lugar superyacente o adyacente al sitio del dolor y/o inflamacion. Un metodo para efectuar el tratamiento sistemico de un sujeto que tiene un trastorno mediado por COX-2, que comprende administrar transdermicamente tal composicion, preferiblemente, poniendo en contacto la composicion con el area de la piel del sujeto, no mayor de 400 cm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29483801P | 2001-05-31 | 2001-05-31 | |
US35075601P | 2001-11-13 | 2001-11-13 | |
PCT/US2002/017067 WO2002096435A2 (en) | 2001-05-31 | 2002-05-30 | Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03010991A true MXPA03010991A (es) | 2004-02-27 |
Family
ID=26968778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03010991A MXPA03010991A (es) | 2001-05-31 | 2002-05-30 | Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. |
Country Status (25)
Country | Link |
---|---|
US (1) | US20030161867A1 (es) |
EP (1) | EP1404345A2 (es) |
JP (1) | JP2004532871A (es) |
KR (1) | KR20040033286A (es) |
CN (1) | CN1547474A (es) |
AP (1) | AP2003002922A0 (es) |
BR (1) | BR0210104A (es) |
CA (1) | CA2448627A1 (es) |
CO (1) | CO5640125A2 (es) |
CR (1) | CR7173A (es) |
CZ (1) | CZ20033241A3 (es) |
EA (1) | EA200301200A1 (es) |
EC (1) | ECSP034869A (es) |
HU (1) | HUP0600294A2 (es) |
IL (1) | IL159100A0 (es) |
IS (1) | IS7055A (es) |
MA (1) | MA27030A1 (es) |
MX (1) | MXPA03010991A (es) |
NO (1) | NO20035325D0 (es) |
OA (1) | OA12613A (es) |
PL (1) | PL367337A1 (es) |
SK (1) | SK14762003A3 (es) |
TN (1) | TNSN03127A1 (es) |
WO (1) | WO2002096435A2 (es) |
ZA (1) | ZA200309298B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4283507B2 (ja) * | 2002-08-02 | 2009-06-24 | 久光製薬株式会社 | 経皮投与用貼付剤 |
US20040126415A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor |
US20050020658A1 (en) * | 2002-11-21 | 2005-01-27 | Katsuyuki Inoo | Selective cyclooxygenase-2 inhibitor patch |
US20040127531A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor |
PL377933A1 (pl) * | 2003-01-23 | 2006-02-20 | Shire Holdings Ag | Formulacja i sposoby leczenia trombocytemii |
CA2541265A1 (en) * | 2003-10-08 | 2005-04-28 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
WO2005044227A1 (en) * | 2003-11-05 | 2005-05-19 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions |
US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
BRPI0519445A2 (pt) * | 2005-01-14 | 2009-01-20 | Lipo Chemicals Inc | composiÇço, formulaÇço de cuidado da pele, mÉtodos para tratar peles de humano e de memÍfero, para prevenir pele de mamÍfero hiperpigmentada, e para praparar uma composiÇço de clareamento da pele |
PE20061303A1 (es) * | 2005-03-30 | 2006-12-07 | Astion Dev As | Composicion farmaceutica que comprende oxaprozina |
EP1890687B1 (en) * | 2005-06-14 | 2008-09-17 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Stable pharmaceutical gel of diclofenac sodium |
US20120040809A1 (en) | 2010-08-11 | 2012-02-16 | Formicola Thomas M | Stretch-Out Roll Up Bar |
US20070243275A1 (en) * | 2006-04-13 | 2007-10-18 | Gilbard Jeffrey P | Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
FR2905601A1 (fr) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques. |
NZ577020A (en) | 2006-10-17 | 2012-05-25 | Nuvo Res Inc | Diclofenac gel containing dimethyl sulfoxide (dmso) |
US7910597B2 (en) | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
HU227970B1 (en) * | 2007-07-10 | 2012-07-30 | Egis Gyogyszergyar Nyrt | Pharmaceutical compositions containing silicones of high volatility |
DE102007034976A1 (de) | 2007-07-26 | 2009-01-29 | Bayer Healthcare Ag | Arzneimittel zur transdermalen Anwendung bei Tieren |
US9050293B2 (en) | 2008-07-16 | 2015-06-09 | Juventio, Llc | Small molecule solubilization system |
CA2739843C (en) | 2008-10-20 | 2018-01-09 | Unilever Plc | Antimicrobial composition comprising thymol and terpineol for disinfecting surfaces |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
PT2424374T (pt) | 2009-05-01 | 2018-04-23 | Advanced Vision Res Inc | Composições de limpeza e métodos para utilização das mesmas |
EA019746B1 (ru) | 2009-09-24 | 2014-05-30 | Юнилевер Нв | Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности |
WO2011041609A2 (en) * | 2009-09-30 | 2011-04-07 | Nuvo Research Inc. | Topical formulations |
EP2485730A1 (en) | 2009-10-09 | 2012-08-15 | Nuvo Research Inc. | Topical formulation comprising etoricoxib and a zwitterionic surfactant |
WO2011149645A1 (en) * | 2010-05-28 | 2011-12-01 | Nuvo Research Inc. | Topical etoricoxib formulation |
EP2575753A1 (en) * | 2010-05-31 | 2013-04-10 | Unilever NV | Skin treatment composition |
JP2012020991A (ja) * | 2010-06-16 | 2012-02-02 | Takasago Internatl Corp | 経皮吸収促進剤、及びこれを含有する皮膚外用製剤 |
WO2012076310A1 (en) | 2010-12-07 | 2012-06-14 | Unilever Nv | An oral care composition |
PL2736491T3 (pl) | 2011-01-04 | 2017-09-29 | Bausch & Lomb Incorporated | Kompozycje bepotastyny |
WO2012131347A1 (en) * | 2011-03-31 | 2012-10-04 | Evocutis Plc | Usnic acid topical formulation |
AU2012320166A1 (en) * | 2011-10-05 | 2014-05-01 | Douglas Pharmaceuticals Ltd. | Pharmaceutical methods and topical compositions containing acitretin |
WO2013064360A2 (en) | 2011-11-03 | 2013-05-10 | Unilever N.V. | A personal cleaning composition |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
US10045965B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
CA2907783C (en) * | 2013-03-29 | 2021-04-06 | Askat Inc. | Therapeutic agent for ocular disease |
CA2932156A1 (en) * | 2013-12-24 | 2015-07-02 | The Procter & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
CA2966843A1 (en) * | 2014-11-10 | 2016-05-19 | Achelios Therapeutics, Inc. | Sprayable analgesic compositions |
ES2895910T3 (es) | 2015-06-30 | 2022-02-23 | Sequessome Tech Holdings Limited | Composiciones multifásicas |
CN105663032A (zh) * | 2016-02-23 | 2016-06-15 | 青岛科技大学 | 一种维他昔布软膏剂的制备方法 |
CN106267218A (zh) * | 2016-10-18 | 2017-01-04 | 华北理工大学 | 4‑萜品醇脂肪酸酯衍生物及其应用和制备方法 |
KR102042456B1 (ko) * | 2018-03-22 | 2019-11-08 | 크리스탈지노믹스(주) | 경피흡수제제 |
CN112203643A (zh) * | 2018-05-31 | 2021-01-08 | 国立大学法人九州大学 | 经皮吸收制剂 |
RU2685436C1 (ru) * | 2018-06-22 | 2019-04-18 | ЗАО "ФармФирма "Сотекс" | Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей |
KR20220001170A (ko) | 2020-06-29 | 2022-01-05 | 김종림 | 앙카볼트 |
KR102619716B1 (ko) * | 2020-10-20 | 2023-12-29 | 고려대학교 산학협력단 | 저온에서도 우수한 항균활성을 갖는 항진균용 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
KR100444802B1 (ko) * | 1995-05-25 | 2004-12-17 | 지.디. 썰 엘엘씨 | 3-할로알킬-1h-피라졸의제조방법 |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
SI9720035B (sl) * | 1996-04-12 | 2009-10-31 | Searle & Co | Substituirani benzensulfonamidni derivati kot predzdravila COX-2 inhibitorjev |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
GB2340751B (en) * | 1998-08-12 | 2003-11-05 | Edko Trading Representation | Pharmaceutical compositions |
ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
WO2000041538A2 (en) * | 1999-01-14 | 2000-07-20 | Noven Pharmaceuticals, Inc. | Dermal compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
WO2000072883A2 (en) * | 1999-06-02 | 2000-12-07 | Aviana Biopharm | Pharmaceutical transdermal compositions |
IN191512B (es) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
WO2002005799A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
IN191090B (es) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
-
2002
- 2002-05-30 EP EP02774123A patent/EP1404345A2/en not_active Withdrawn
- 2002-05-30 CZ CZ20033241A patent/CZ20033241A3/cs unknown
- 2002-05-30 MX MXPA03010991A patent/MXPA03010991A/es unknown
- 2002-05-30 JP JP2002592944A patent/JP2004532871A/ja not_active Withdrawn
- 2002-05-30 HU HU0600294A patent/HUP0600294A2/hu unknown
- 2002-05-30 US US10/158,342 patent/US20030161867A1/en not_active Abandoned
- 2002-05-30 CN CNA028149467A patent/CN1547474A/zh active Pending
- 2002-05-30 AP APAP/P/2003/002922A patent/AP2003002922A0/en unknown
- 2002-05-30 CA CA002448627A patent/CA2448627A1/en not_active Abandoned
- 2002-05-30 EA EA200301200A patent/EA200301200A1/ru unknown
- 2002-05-30 PL PL02367337A patent/PL367337A1/xx not_active Application Discontinuation
- 2002-05-30 IL IL15910002A patent/IL159100A0/xx unknown
- 2002-05-30 WO PCT/US2002/017067 patent/WO2002096435A2/en not_active Application Discontinuation
- 2002-05-30 KR KR10-2003-7015581A patent/KR20040033286A/ko not_active Application Discontinuation
- 2002-05-30 OA OA1200300310A patent/OA12613A/en unknown
- 2002-05-30 SK SK1476-2003A patent/SK14762003A3/sk unknown
- 2002-05-30 BR BR0210104-1A patent/BR0210104A/pt not_active IP Right Cessation
- 2002-05-30 TN TNPCT/US2002/017067A patent/TNSN03127A1/fr unknown
-
2003
- 2003-11-27 IS IS7055A patent/IS7055A/is unknown
- 2003-11-28 CO CO03105192A patent/CO5640125A2/es not_active Application Discontinuation
- 2003-11-28 MA MA27417A patent/MA27030A1/fr unknown
- 2003-11-28 CR CR7173A patent/CR7173A/es not_active Application Discontinuation
- 2003-11-28 EC EC2003004869A patent/ECSP034869A/es unknown
- 2003-11-28 ZA ZA200309298A patent/ZA200309298B/xx unknown
- 2003-11-28 NO NO20035325A patent/NO20035325D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1547474A (zh) | 2004-11-17 |
EP1404345A2 (en) | 2004-04-07 |
TNSN03127A1 (fr) | 2005-12-23 |
SK14762003A3 (sk) | 2004-08-03 |
WO2002096435A2 (en) | 2002-12-05 |
JP2004532871A (ja) | 2004-10-28 |
IS7055A (is) | 2003-11-27 |
ZA200309298B (en) | 2004-05-12 |
CZ20033241A3 (cs) | 2004-08-18 |
WO2002096435A3 (en) | 2003-05-01 |
KR20040033286A (ko) | 2004-04-21 |
OA12613A (en) | 2006-06-09 |
IL159100A0 (en) | 2004-05-12 |
US20030161867A1 (en) | 2003-08-28 |
BR0210104A (pt) | 2004-06-08 |
CR7173A (es) | 2004-04-22 |
HUP0600294A2 (en) | 2007-02-28 |
MA27030A1 (fr) | 2004-12-20 |
CA2448627A1 (en) | 2002-12-05 |
AP2003002922A0 (en) | 2003-12-31 |
PL367337A1 (en) | 2005-02-21 |
CO5640125A2 (es) | 2006-05-31 |
ECSP034869A (es) | 2004-07-23 |
EA200301200A1 (ru) | 2004-06-24 |
NO20035325D0 (no) | 2003-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010991A (es) | Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. | |
WO2003080022A3 (en) | Analgesics for nasal administration | |
PT957900E (pt) | Composicoes e metodos para aplicacao topica de agentes terapeuticos | |
WO2004105702A3 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
PT942724E (pt) | Formulacoes em gel para libertacao topica de farmacos | |
DE69826644D1 (de) | Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker | |
WO2002013873A3 (en) | P97-active agent conjugates and their methods of use | |
WO2005043971A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
RS20060479A (en) | Novel compositions for topical delivery | |
WO2008157103A3 (en) | Modified release solid or semi-solid dosage forms | |
ATE347879T1 (de) | Transdermale pharmazeutische zusammensetzung zur wirkstoffverabreichung | |
WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
GEP20043216B (en) | Orally Administered Controlled Drug Delivery System | |
WO2005007072A3 (en) | Methods and pharmaceutical compositions for healing wounds | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
SG146638A1 (en) | Pharmaceutical delivery system | |
WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
WO2006091719A3 (en) | Compositions and methods enhancing transdermal delivery of drugs and biologics | |
AR008886A1 (es) | Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea | |
BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
WO2001041771A3 (de) | Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne | |
Giusti et al. | Alternative Routes for Systemic Opioid Delivery |